Summit Therapeutics Enters $380M At-the-Market Equity Program

What Happened

• Summit Therapeutics Inc. announced on July 23, 2026 that it entered into a Distribution Agreement with J.P. Morgan Securities LLC under which the company may sell, from time to time, shares of its common stock having an aggregate offering price of up to $380,000,000.
• The sales would be conducted as an “at-the-market” offering (Rule 415(a)(4)) and may occur on the Nasdaq Global Market or other trading venues, through market makers, in block or negotiated transactions. The company is not obligated to sell any shares and may suspend or stop sales at any time.
• The offering will be made pursuant to Summit’s effective Form S-3 registration statement (File No. 333-296642); a prospectus supplement was filed with the SEC on July 23, 2026.

Key Details

• Aggregate offering capacity: up to $380,000,000 of common stock.
• Sales agent: J.P. Morgan Securities LLC (acting as sales agent).
• Sales commission: up to 3.0% of the gross sales price per share sold through the Sales Agent.
• Date of agreement and prospectus supplement filing: July 23, 2026.

Why It Matters

• This gives Summit Therapeutics a flexible way to raise equity capital over time without a firm commitment to sell shares immediately, which can help fund operations, development programs, or other corporate needs.
• Because sales can occur at prevailing market prices, actual capital raised will depend on market conditions and the company’s decisions about timing and amount of sales.
• Investors should note potential dilution if Summit chooses to sell shares under this program; commission costs and timing of sales may also affect existing shareholders.